Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids

Cardiovascular Research

Volumn 42, Issue 3, 1999, Pages 752-760

  Verhaar, Marianne C ^a   Honing, Marina L H ^a   Van Dam, Thea ^a   Zwart, Mirjam ^b   Koomans, Hein A ^a   Kastelein, John J P ^b   Rabelink, Ton J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Calcium antagonist; Endothelium; Familial hypercholesterolemia; Forearm; Human; Nitric oxide

Indexed keywords

CALCIUM ANTAGONIST; CHOLESTEROL; NIFEDIPINE; NITRIC OXIDE; SEROTONIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOREARM BLOOD FLOW; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MALE; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ADULT; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; NITROPRUSSIDE; RECOMBINANT PROTEINS; REGIONAL BLOOD FLOW; SEROTONIN; TIME FACTORS; VASODILATOR AGENTS;

EID: 0032991031     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00341-1     Document Type: Article

References (73)

1. Henry P.D., Bentley K.I. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest. 68:1981;1366-1369.
2. Willis A.L., Nagel B., Churchill V.et al. Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Arteriosclerosis. 5:1985;250-255.
3. Lichtor T., Davis H.R., Vesselinovitch D., Wissler R.W., Mullan S. Suppression of atherogenesis by nifedipine in the cholesterol-fed rhesus monkey. Appl Pathol. 7:1989;8-18.
4. Habib J.B., Bossaller C., Wells S., Williams C., Morrisett J.D., Henry P.D. Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110. Circ Res. 58:1986;305-309.
5. Lichtlen P.R., Hugenholtz P.G., Rafflenbeul W., Hecker H., Jost S., Deckers J.W. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet. 335:1990;1109-1113.
6. Waters D., Lesperance J., Francetich M.et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 82:1990;1940-1953.
7. Johnson H. Effects of nifedipine (Adalat) on platelet function in vitro and in vivo. Thromb Res. 21:1981;523-528.
8. McDonagh P.F., Rauzzino M.J. Stimulated leukocyte adhesion in coronary microcirculation is reduced by a calcium antagonist. Am J Physiol. 34:1993;H476-483.
9. Alexander J.J., Miguel R., Piotrowski J.J. The effect of nifedipine on lipid and monocyte infiltration of the subendothelial space. J Vasc Surg. 17(5):1993;841-847.
10. Viele D., Betz E. Effect of the calcium entry blocker, Flunarizine, on ruthenium red uptake by endothelial cells following acute electrical stimulation of rabbit carotid arteries. Basic Res Cardiol. 80(1):1985;58-65.
11. Tedgui A., Chiron B., Curmi P., Juan L. Effect of nicardipine and verapamil on in vitro albumin transport in rabbit thoracic aorta. Arteriosclerosis. 7(1):1987;80-87.
12. Nakao J., Ito H., Ooyama T., Chang W.C., Murota S. Calcium dependency of aortic smooth muscle cell migration induced by 12-L-hydroxy-5,8,10,14-eico-satetraenoic acid. Atherosclerosis. 46:1983;309-319.
13. McMurray H.F., Chahwala S.B. Amlodipine exerts a potent antimigrational effect on aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 20(Suppl A):1992;S54-56.
14. Jackson L.J., Bush R.C., Bowyer D.E. Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size. Atherosclerosis. 69:1988;115-122.
15. Handley D.A., Van Valen R.G., Melden M.K., Saunders R.N. Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110. Am J Pathol. 124(1):1986;88-93.
16. Yang Z., Noll G., Luscher T.F. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation. 88(3):1993;832-836.
17. Becker R.H.A., Linz W., Wiemer G., Nordlander M. Low-dose felodipine treatment attenuates endothelial dysfunction in rabbits fed an atherogenic diet. J Cardiovasc Pharmacol. 18(Suppl.10):1991;S36-41.
18. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. New Engl J Med. 329(27):1993;2002-2012.
19. Egashira K., Inou T., Hirooka Y.et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 91(1):1993;29-37.
20. Stroes E.S., Koomans H.A., de Bruin T.W.A., Rabelink T.J. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 346:1995;467-471.
21. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95(5):1997;1126-1131.
22. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. New Engl J Med. 332(8):1995;488-493.
23. Ting H.H., Timimi F.K., Haley E.A., Roddy M.A., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolaemia. Circulation. 95(12):1997;2617-2622.
24. Familial hypercholesterolaemia. In: Goldstein JL, Brown MS, Stanbury JB, Wyngaarden JB, Frederickson DS, Goldstein JL, Brown MS, editors. The metabolic basis of inherited disease. 5th ed, New York:McGraw-Hill, 1983;672-712.
25. Lombardi P., Sijbrands E.J.G., van de Giessen K.et al. Mutations in the low density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing. J Lipid Res. 36:1995;860-867.
26. Chang P.C., Verlinde R., Bruning T., van Brummelen P. A microcomputer-based, R-wave triggered system for hemodynamic measurements in the forearm. Comput Biol Med. 18(3):1988;157-163.
27. Bruning T.A., van Zwieten P.A., Blauw G.J., Chang P.C. No functional involvement of 5-hydroxytryptamine 1a receptors in nitric oxide dependent dilation caused by serotonin in the human forearm vascular bed. J Cardiovasc Pharmacol. 24:1994;454-461.
28. Stroes E.S., Luscher T.F., de Groot F.G., Koomans H.A., Rabelink T.J. Cyclosporin A increases nitric oxide activity in vivo. Hypertension. 29(2):1997;570-575.
29. Verhaar M.C., Strachan F.E., Newby D.E.et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 97:1998;752-756.
30. Vallance P., Collier J., Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. II:1989;997-999.
31. Calver A., Collier J., Vallence P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest. 90:1992;2548-2554.
32. Fontijn R., Hop C., Brinkman H.J.et al. Maintenance of vascular endothelial cell-specific properties after immortalization with an amphotrophic replication-deficient retrovirus containing human papilloma virus 16 E6/E7 DNA. Exp Cell Res. 216(1):1995;199-207.
33. Henry P.D. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol. 46:1980;1047-1058.
34. Opie L.H. Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis. XXXVIII(4):1996;273-290.
35. Rosenkranz-Weiss P., Sessa W.C., Milstien S., Kaufman S., Watson C.A., Pober J.S. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. J Clin Invest. 93:1994;2236-2243.
36. Herbette L.G., Vant Erve Y.M.H., Rhodes D.G. Interaction of 1,4-dihydropyridine calcium channel antagonists with biological membranes: lipid bilayer partitioning could occur before drug binding to receptors. J Mol Cell Cardiol. 21:1989;187-201.
37. Jaffe E.A., Nachman R.L., Becker C.G., Minich C.R. Culture of human endothelial cells derived from umbilical cord veins. Identification of morphology and immunologic criteria. J Clin Invest. 52:1973;2745-2756.
38. Balasoiu D., van Kessel K.C., van Kats-Renaud H.J., Collet T.J., Hoepelman A.I. Granulocyte function in women with diabetes and asymptomatic bacteriuria. Diabetes Care. 20(3):1997;392-395.
39. Benjamin N., Calver A., Collier J., Robinson B., Vallance P., Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension. 25(5):1995;918-923.
40. Gilligan D.M., Guetta V., Panza J.A., Garcia C.E., Quyyumi A.A., Cannon R.O. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation. 90(1):1994;35-41.
41. Casino P.R., Kilcoyne C.M., Cannon R.O., Quyyumi A.A., Panza J.A. Impaired endothelium-dependent vascular relaxation in patients with hypercholesterolemia extends beyond the muscarinic receptor. Am J Cardiol. 75:1995;40-44.
42. Flavahan N.A. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation. 85(5):1992;1927-1938.
43. Kiowski W., Bracht C., Yan X.W.et al. Isradipine improves endothelium-mediated vasodilation in patients with hyperlipidemia independent of changes in cholesterol (Abstract). Am J Hypertens. 10:1997;24A.
44. Taddei S., Virdis A., Ghiadoni L.et al. Nifedipine enhances endothelium-dependent relaxations and inhibits contractions to endothelin-1 and phenylephrine in human hypertension (Abstract). Circulation. 96(8):1997;762-763.
45. Frielingsdorf J., Seiler C., Kaufmann P., Vassalli G., Suter T., Hess O.M. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation. 93(7):1996;1380-1387.
46. Kaufmann P.A., Frielingsdorf J., Mandinov L., Seiler C., Hug R., Hess O.M. Reversal of abnormal coronary vasomotion by calcium antagonists in patients with hypercholesterolemia. Circulation. 97:1998;1348-1354.
47. Benzuly K.H., Padgett R.C., Kaul S., Piegors D.J., Armstrong M.L., Heistad D.D. Functional improvement precedes structural regression of atherosclerosis. Circulation. 89(4):1994;1810-1818.
48. Davis S.F., Yeung A.C., Meredith I.T.et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year post-transplant. Circulation. 93(3):1996;457-462.
49. Leung W., Lau C., Wong C. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 341:1993;1496-1500.
50. Egashira K., Hirooka Y., Kai H.et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89(6):1994;2519-2524.
51. Scandinavian Simvastatin Survival Study Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9.
52. Watts G.F., Lewis B., Brunt J.N.H.et al. Effects on coronary artery disease of lipid-lowering diet or diet plus cholestyramine in the St Thomas Atherosclerosis Regression Study (STARS). Lancet. 339:1992;563-569.
53. Shepherd J., Cobbe S.M., Ford I.et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New Engl J Med. 333(20):1995;1301-1307.
54. Pitt B., Mancini G.B.J., Ellis S.G., Rosman H.S., Park J.S., McGovern M.E. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 26:1995;1133-1139.
55. Sacks F.M., Pfeffer M.A., Moye L.A.et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med. 335:1996;1001-1009.
56. Jukema J.W., Zwinderman A.H., van Boven A.J.et al. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. Arterioscler Thromb Vasc Biol. 16(3):1996;425-430.
57. Staessen J.A., Fagard R., Thijs L.et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 350:1997;757-764.
58. Gong L., Zhang W., Zhu Y.et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 14:1996;1237-1245.
59. Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 92:1995;1326-1331.
60. Davis B.R., Cutler J.A., Gordon D.J.et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens. 9:1996;342-360.
61. Brown M.J., Castaigne A., Ruilope L.M.et al. INSIGHT: international nifedipine GITS study intervention as a goal in hypertension treatment. J Hum Hypertens. 10(Suppl 3):1996;S157-S160.
62. 2+ channel antagonists. Trends Pharmacol Sci. 13(6):1992;256-262.
63. Kaasjager K.A.H., Koomans H.A., Rabelink T.J. Effectiveness of enalapril versus nifedipine to antagonize blood pressure and the renal response to endothelin in humans. Hypertension. 25:1995;620-625.
64. Zhang X., Hintze T.H. Amlodipine releases nitric oxide from canine coronary microvessels. An unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 97:1998;576-580.
65. Harrison D.G., Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am J Cardiol. 75(6):1995;75B-81B.
66. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 91(6):1993;2546-2551.
67. Mak I.T., Weglicki W.B. Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res. 66(5):1990;1449-1452.
68. Mason R.P., Trumbore M.W. Differential membrane interactions of calcium channel blockers. Implications for antioxidant activity. Biochem Pharmacol. 51:1996;653-660.
69. Aruoma O.I., Smith C., Cecchini R., Evans P.J., Halliwell B. Free radical scavenging and inhibition of lipid peroxidation by beta-blockers and by agents that interfere with calcium metabolism. Biochem Pharmacol. 42(4):1991;735-743.
70. Mak I.T., Boehme P., Weglicki W.B. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res. 70(6):1992;1099-1103.
71. Lupo E., Locher R., Weisser B., Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with α-tocopherol. Biochem Biophys Res Commun. 203(3):1994;1803-1808.
72. Lesnik P., Dachet C., Petit L.et al. Impact of a combination of a calcium antagonist and a beta-blocker on cell- and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells. Arterioscler Thromb Vasc Biol. 17(5):1997;979-988.
73. Kauder W.F., Watts J.A. Antioxidant properties of dihydropyridines in isolated rat hearts. Biochem Pharmacol. 51:1996;811-819.